Clinical Trial

Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain

Study acronym: KALPAS
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study utilizes a 3-arm placebo-controlled RCT to study the effectiveness of ketamine in reducing chronic post-mastectomy pain. Participants randomized to the first arm will receive a 0.35 mg/kg dose after induction, followed by a 0.25 mg/kg/hr infusion during surgery (up to a maximum of 6 hours) and continued for 2 hours postoperatively. Participants in the second arm will receive a single dose of 0.6 mg/kg of ketamine in the post-anesthesia care unit, and the final group will serve as the control group and receive saline (no ketamine).
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2021-08-31; most recent amendment 2026-06-04.
Status change: Recruiting → Active, Not Recruiting 2025-04-10
Status change: Not Yet Recruiting → Recruiting 2022-03-02
Trial Details
NCT Number NCT05037123
Lead Sponsor NYU Langone Health
Collaborators: National Cancer Institute (NCI)
Conditions Chronic Postsurgical Pain
Enrollment 765 participants
Start Date 2022-01-04
Primary Completion 2025-05-28 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-08